Conecte-se

Bibliografias temáticas / Clozapine / Livros

Siga este link para ver outros tipos de publicações sobre o tema: Clozapine.

Livros sobre o tema "Clozapine"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 25 de julho de 2025

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores livros para estudos sobre o assunto "Clozapine".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os livros das mais diversas áreas científicas e compile uma bibliografia correta.

1

author, Taylor David, ed. Clozapine handbook. Lloyd-Reinhold Communications, 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

1941-, Jones Barry, Lapierre Yvon D, Canadian Psychiatric Association Meeting, Royal Society of Medicine Services (Great Britain), and Sandoz Canada, eds. Clozapine in treatment-resistant schizophrenia: A scientific update. Royal Society of Medicine Services, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Y, Meltzer Herbert, ed. Clozapine: A 5-year perspective and clinical recommendations. Physicians Postgraduate Press, 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Glennie, Judith. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Canadian Coordinating Office for Health Technology Assessment, 1997.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Lundberg, Tommie. Clozapine - an atypical neoroleptic: A pharmacokinetic, PET and clinical study. Uppsala University, 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Masellis, Mario. Pharmacogenetic analysis of serotonin receptors and clinical response to clozapine in schizophrenia patients. National Library of Canada = Bibliothèque nationale du Canada, 1999.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Naber, D., F. Müller-Spahn, and F. G. Pajonk, eds. Clozapin. Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60551-2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

1954-, Watkins Linda R., and Maier Steven F, eds. Cytokines and pain. Birkhauser Verlag, 1999.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

United States. Congress. Senate. Committee on the Judiciary. Subcommittee on Antitrust, Monopolies, and Business Rights. Marketing of Clozaril: Improved safety or barrier to access : hearing before the Subcommittee on Antitrust, Monopolies and Business Rights of the Committee on the Judiciary, United States Senate, One Hundred Second Congress, first session, on the marketing of Clozaril, a drug for the treatment of schizophrenia, March 5, 1991. U.S. G.P.O., 1991.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Naber, Dieter, and Franz Müller-Spahn, eds. Clozapin Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-93547-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Naber, Dieter, and Franz Müller-Spahn, eds. Clozapin Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-93565-7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Sirfy, Ahmad. Dopamimetische Psychose bei Patienten mit idiopathischem Parkinson-Syndrom und verwandten Erkrankungen - eine retrospektive Analyse der Clozapin-Plasmaspiegel, der Dosis-Spiegel-Relation und Einflussfaktoren auf die Clozapin-Plasmaspiegel bei bestehender Clozapin-Medikation. s.n.], 2013.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Clozapine: The atypical antipsychotic. Royal College of Psychiatrists, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Meyer, Jonathan M., and Stephen M. Stahl. Clozapine Handbook: Stahl's Handbooks. University of Cambridge ESOL Examinations, 2021.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Clozapine Handbook: Stahl's Handbooks. Cambridge University Press, 2019.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Lane, Chadrick, and Vinod H. Srihari. Clozapine for Treatment-Resistant Schizophrenia. Edited by Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari, and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0040.

Texto completo da fonte

Resumo:

This chapter provides a summary of a landmark study on the pharmacologic management of treatment-resistant schizophrenia. This clinical trial, conducted by Kane and colleagues, asks whether clozapine is an effective option in the care of patients with treatment-resistant schizophrenia who have not responded to past trials of first-generation antipsychotics. To answer this question, the chapter reviews the basics of the study, including funding sources, study location, inclusion and exclusion criteria, number of participants, research design, interventions, follow-up, endpoints, results, critic

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Barron, Daniel, and Noah Capurso. Clozapine for Suicidality in Schizophrenia. Edited by Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari, and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0046.

Texto completo da fonte

Resumo:

Patients with schizophrenia have a 50% risk of a suicide attempt during their life, with a nearly an estimated 10% risk of completed suicide. Decreasing this risk is an urgent clinical concern. This chapter provides a summary of a landmark study on how to reduce suicidality in patients with schizophrenia, specifically whether clozapine reduces suicidal events in patients with schizophrenia. This chapter describes the outline of the study, including fundings sources, study locations, the patient population and how many were studied, the study design and intervention through to follow-up, endpoi

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Rohde, Christopher, and Jimmi Nielsen. Managing common adverse effects of clozapine. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.003.0007.

Texto completo da fonte

Resumo:

Adverse effects during clozapine treatment are common, and can be divided into very common (>10%: constipation, weight gain, metabolic side effects, sedation, and sialorrhea), common (1–10%: seizures and enuresis), and cardiac (sinus tachycardia, electrocardiogram abnormalities, and orthostatic hypotension) adverse effects. Most adverse effects are benign, but often reduce the quality of life for the patient, leading to reduced adherence and thereby psychotic relapse. As a consequence, treatment of these adverse effects is important and should not be neglected. In this chapter, we present s

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Leponex: Informationen für Betroffene, ihre Angehörigen und Freunde. Pm-Verlag, 2007.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Yuen, Eunice, and Cenk Tek. Effectiveness of Clozapine versus Other Atypical Antipsychotics. Edited by Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari, and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0041.

Texto completo da fonte

Resumo:

This chapter provides a summary of a landmark study on adult patients with schizophrenia. Discussion here is based on the investigation from the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE). What is the role of clozapine among patients with chronic schizophrenia who fail to respond to atypical antipsychotics? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews oth

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Lerner, Vladimir. Clozapine: Medical Uses, Interactions and Side Effects. Nova Science Publishers, Incorporated, 2020.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Chanoch, Miodownik, Amir Krivoy, and Vladimir Lerner. Clozapine: Medical Uses, Interactions and Side Effects. Nova Science Publishers, Incorporated, 2020.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Brown, Julia. Clozapine Clinic: Health Agency in High-Risk Conditions. Taylor & Francis Group, 2022.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Brown, Julia E. H. Clozapine Clinic: Health Agency in High-Risk Conditions. Routledge, 2022.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Brown, Julia. Clozapine Clinic: Health Agency in High-Risk Conditions. Taylor & Francis Group, 2022.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Brown, Julia. Clozapine Clinic: Health Agency in High-Risk Conditions. Taylor & Francis Group, 2022.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Yang, Yvonne, and Stephen Marder. Pharmacological management of treatment-resistant schizophrenia: fundamentals of clozapine. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.003.0006.

Texto completo da fonte

Resumo:

Evidence from controlled clinical trials supports the prescribing of clozapine for patients with treatment-resistant schizophrenia (TRS). Early studies focused on severely ill TRS patients. More recent studies indicate that clozapine can be effective for patients who are relatively stable but are burdened by persistent psychotic symptoms. Clozapine treatment is associated with a substantial side effect burden, including sedation, orthostasis, weight gain, constipation, and seizures. In addition, because of a risk of potentially fatal agranulocytosis, clozapine patients require regular monitori

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Barnes, Thomas R. E. Pharmacological management of treatment-resistant schizophrenia: alternatives to clozapine. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.003.0009.

Texto completo da fonte

Resumo:

Other than for clozapine, there are no pharmacological interventions with robust evidence of a positive benefit–risk balance for the treatment-resistant schizophrenia. For patients with treatment-resistant schizophrenia, there is usually little to be gained, in comparison to switching the antipsychotic to clozapine, from alternatives such as a further switch to a non-clozapine antipsychotic medication, the prescription of high-dose or combined antipsychotic medications, or the augmentation of continuing antipsychotic medication with other medications, such as antidepressants, mood stabilizers,

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Clozapine congeners: Structural requirements for dopamine D4 receptor selectivity. National Library of Canada = Bibliothèque nationale du Canada, 1995.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Gee, Siobhan, and David Taylor. Pharmacological management of treatment-resistant schizophrenia: advanced use of clozapine. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.003.0008.

Texto completo da fonte

Resumo:

Clozapine is licensed in the UK for use in treatment-resistant schizophrenia, treatment-intolerant schizophrenia, or psychosis associated with Parkinson’s disease. As with many drugs, it is also used outside of these licensing parameters for other conditions or clinical situations—often referred to as ‘off-label’ prescribing. These off-label indications have varying degrees of theoretical support, peer-reviewed evidence, and practical experience associated with them. This chapter discusses the use of clozapine for children and adolescents, older adults, and in the treatment of aggression and m

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Lapierre, Y. Clozapine in Treatment-resistant Schizophrenia: A Scientifid Update (International Congress & Symposium). Royal Society of Medicine Press Ltd, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Publications, ICON Health. Clozapine - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Bond, Stephen. Impact of the pharmacist on resource utilization in an outpatient adult clozapine clinic. 1996.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Rowling, Corene. CLOZAPINE: A Prescription Drug Used to Treat a Schizoaffective Disorders or Psychotic Mood Issue. Independently Published, 2019.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Remington, Gary, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee, and Araba Chintoh. Ultra-treatment resistance. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.003.0012.

Texto completo da fonte

Resumo:

Ultra-treatment resistance or ultra-resistant schizophrenia is defined as describing individuals who meet criteria for treatment-resistant schizophrenia and receive an adequate trial of clozapine in the absence of other confounding factors that might compromise response (e.g. substance abuse, antipsychotic non-adherence), but demonstrate a suboptimal response. Because the definition currently hinges on a trial of clozapine, ‘clozapine-resistant schizophrenia’ has also been proposed as a more precise descriptor. This chapter reviews issues specific to classifying this subpopulation, including e

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Howes, Oliver, ed. Treatment Response and Resistance in Schizophrenia. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.001.0001.

Texto completo da fonte

Resumo:

Schizophrenia and other psychotic disorders are common mental illnesses, but their treatment is complex. This book provides a state-of-the-art overview of their treatment, with a focus on the real-world challenges faced by clinicians and patients. It brings together contributions from leading experts from around the world to cover key conceptual issues, including how to evaluate response, the nature of treatment resistance, ultra-medication (clozapine) treatment resistance, and pseudo-resistance, and how to choose a first-line antipsychotic drug that maximizes response and minimizes side effec

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Hwang, Rudi. Pharmacogenetic analysis of dopamine receptor gene polymorphisms and clinical response to clozapine in patients with schizophrenia. 2006.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Abbas, Atheir I., and Jeffrey A. Lieberman. Pharmacological Treatments for Schizophrenia. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0006.

Texto completo da fonte

Resumo:

Schizophrenia, a chronic mental disorder, has a lifetime prevalence rate of approximately 1%. The first antipsychotic drug, chlorpromazine, was introduced in 1954, followed by several similar drugs. With the introduction of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and more recently paliperidone, iloperidone, asenapine, and lurasidone, antipsychotic drugs are often classified as first generation or typical (chlorpromazine-like) versus second generation or atypical (clozapine-like), although the distinction between the two classes, particularly with respect to e

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Smith, Robert C., Stefan Leucht, and John M. Davis. Maximizing response to first-line antipsychotics in schizophrenia. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.003.0003.

Texto completo da fonte

Resumo:

The choice of first-line antipsychotic treatment for patients with schizophrenia should balance considerations of differential efficacy of antipsychotics against the relative risk of different side effects. In terms of efficacy, recent meta-analyses have shown that antipsychotics are not equivalent in efficacy. Clozapine, amisulpride, olanzapine, and risperidone show small to moderate, but statistically significant, differences, indicating greater efficacy compared to a number of other antipsychotics on some primary efficacy outcome measures. Amisulpride and cariprazine have the strongest evid

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Burns, Tom, and Mike Firn. The role of medication. Edited by Tom Burns and Mike Firn. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198754237.003.0007.

Texto completo da fonte

Resumo:

This chapter focuses mainly on the importance of maintenance antipsychotic medication and mood stabilizers. It examines procedures to support persistence with these drugs and maintain engagement. The techniques for initiating and monitoring clozapine therapy in the community for patients with resistant schizophrenia are outlined. The practical processes for ensuring and conducting regular structured reviews of long-term medication, both to assess progress and to identify side effects, are described in detail. In addition, the judicious use of antidepressants and benzodiazepines is outlined.

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Burns, Tom, and Mike Firn. Schizophrenia and delusional disorders. Edited by Tom Burns and Mike Firn. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198754237.003.0015.

Texto completo da fonte

Resumo:

Schizophrenia is the iconic mental illness. This chapter describes the evolution of the concept by doctors in the early mental hospitals through to modern classifications of its subtypes. The nature/nurture controversy has been particularly fraught in schizophrenia and the possible role of the family in its genesis is considered in detail. Explanatory models such as the ‘schizophrenogenic mother’ and the ‘double bind’, although now only historical, are described because of their hold on the popular imagination. Family factors (‘expressed emotion’) in the maintenance of the disorder are also co

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Schulz, S. Charles, and Robert O. Friedel. Established and Novel Pharmacological Approaches to the Treatment of Personality Disorders. Edited by Christian Schmahl, K. Luan Phan, Robert O. Friedel, and Larry J. Siever. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199362318.003.0016.

Texto completo da fonte

Resumo:

In the past few decades, the widely held belief of personality disorder patients being unresponsive to medication has been challenged. This chapter first reviews the current knowledge on medication for patients with personality disorders and then considers a number of novel pharmacological approaches that may yield additional beneficial results in the treatment of these disorders. It utilizes the neuroscience-based nomenclature for psychotropic agents, in which the presumptive modes and mechanisms of action of each drug form the basis of the nomenclature. A special emphasis of the chapter is l

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Ellison, Justin C., Jason B. Rosenstock, and Michael J. Marcsisin. Somatic Treatments for Psychotic Disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199331505.003.0006.

Texto completo da fonte

Resumo:

A variety of somatic therapies can be used to treat individuals suffering from psychosis. Most commonly, providers will prescribe antipsychotics, which generally block dopamine receptors and are particularly useful at reducing positive symptoms. Second-generation antipsychotics have fewer movement side effects than older agents do, but they are more expensive and have more metabolic side effects. Long-acting injectable (LAI) antipsychotics can be useful for improving outcomes, especially in non-adherent patients, and clozapine is the gold standard for treatment-refractory psychosis. Other agen

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Rose, Raquel, and Nicolette Molina. Interventions. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190260859.003.0010.

Texto completo da fonte

Resumo:

Despite the fact that suicide is one of the leading causes of death in the United States, there are currently no US Food and Drug Administration-approved treatments for suicidal behavior. However, interventions that provide potentially effective treatment are available. This chapter explores medications and biological interventions as well as psychosocial, alternative, and app/Internet-based interventions. The section on medications and biological interventions covers clozapine, lithium, and ketamine. The psychosocial intervention section covers dialectical behavior therapy, cognitive–behavior

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Douglas, Kevin S., Tonia L. Nicholls, and Johann Brink. Interventions for the Reduction of Violence by Persons with Serious Mental Illnesses. Edited by Phillip M. Kleespies. Oxford University Press, 2016. http://dx.doi.org/10.1093/oxfordhb/9780199352722.013.34.

Texto completo da fonte

Resumo:

Violence perpetrated by persons with serious mental illness (SMI), although certainly not the norm among this group, is of clinical and legal import in numerous legal settings. Among these are civil commitment, forensic psychiatry (insanity acquittees), and the criminal justice system. In this chapter, we provide a critical review of interventions and their empirical support that are used to reduce violence among persons with SMI. Promising findings support the use of cognitive behavioral, social learning, and cognitive skills approaches that are consistent with the Risk-Need-Responsivity (RNR

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Tracy, Derek K., and Fiona Gaughran. Treatment with medication: Side effects, adherence, and risk. Edited by Alec Buchanan and Lisa Wootton. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198738664.003.0009.

Texto completo da fonte

Resumo:

Antipsychotic medications revolutionized the care of psychosis, but they have brought with them significant side effects and issues around adherence; these latter factors, and informed co-working with patients, are primary drivers for specific medication choices. The data remain limited for polypharmacy and above-maximum dose prescribing, though there may be individuals for whom this is considered. Long-acting injectables (LAIs or ‘depots’) have a good evidence base, and are probably underutilized, though clozapine remains our drug of choice in refractory illness. Forensic-population data show

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

(Editor), Bart A. Ellenbroek, and Alexander R. Cools (Editor), eds. Atypical Antipsychotics (Milestones in Drug Therapy). Birkhäuser Basel, 2000.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Beiner, Heike Anne-Marie. Auswirkungen von Clozapin auf das Elektroenzephalogramm. 1999.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Kückelmann, Stephan. Zur Wirksamkeit von Clozapin bei Spätdyskinesien. 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Leppig, Manuela. Zur Wirksamkeit von Clozapin bei ambulanter Langzeitbehandlung. 1989.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!